Jade Coats, OD: AbbVie/Allergan: Advisory Committee/Board Member (); Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Bausch Health: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Dompe: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Harrow Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Orasis: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Sun Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Tarsus Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Tenpoint: Advisory Committee/Board Member (); Thea Pharma: Advisory Committee/Board Member (); ZEISS: Advisory Committee/Board Member (), Consulting Fees ()
This course examines the evolving landscape of pharmaceutical therapies for presbyopia, with a focus on emerging agents beyond pilocarpine. Attendees will explore novel mechanisms of action, investigational drugs in development, and the potential impact these therapies may have on presbyopia management. Emphasis will be placed on clinical trial data, patient selection considerations, and how these therapies may integrate into future optometric practice.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Review investigational pharmaceutical agents currently being studied for presbyopia management.
Understand the different mechanisms of action targeted by emerging presbyopia therapies.
Discuss safety profiles, efficacy data, and limitations of drugs in clinical development.
Anticipate how new pharmaceutical options may influence patient expectations and presbyopia care pathways.
Recognize areas of ongoing research and potential future directions in presbyopia drug development.
